These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 25572784)

  • 1. Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis.
    Abdel-Rahman O; Fouad M
    Future Oncol; 2015; 11(1):79-90. PubMed ID: 25572784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):477-86. PubMed ID: 25665062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.
    Peng L; Zhou Y; Ye X; Zhao Q
    Tumour Biol; 2015 Feb; 36(2):643-54. PubMed ID: 25281033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J; Tian D
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):30-41. PubMed ID: 23830806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2014 Dec; 14(12):1529-36. PubMed ID: 25159115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Opin Drug Saf; 2014 Aug; 13(8):999-1008. PubMed ID: 24930544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2015; 15(7):847-58. PubMed ID: 25994247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.
    Garcia CA; Wu S
    Cancer Invest; 2016 Nov; 34(10):521-530. PubMed ID: 27791402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.
    Shameem R; Hamid MS; Wu S
    Anticancer Res; 2015 Apr; 35(4):2333-40. PubMed ID: 25862897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
    Shameem R; Lacouture M; Wu S
    Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic complications with the use of mTOR inhibitors for cancer therapy.
    Sivendran S; Agarwal N; Gartrell B; Ying J; Boucher KM; Choueiri TK; Sonpavde G; Oh WK; Galsky MD
    Cancer Treat Rev; 2014 Feb; 40(1):190-6. PubMed ID: 23684373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-related mortality with everolimus in cancer patients.
    Wesolowski R; Abdel-Rasoul M; Lustberg M; Paskell M; Shapiro CL; Macrae ER
    Oncologist; 2014 Jun; 19(6):661-8. PubMed ID: 24794158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus in renal cell carcinoma.
    Wang Y
    Drugs Today (Barc); 2010 Aug; 46(8):557-66. PubMed ID: 20830316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
    Jebali M; Elaidi R; Brizard M; Fouque J; Takouchop C; Sabatier B; Oudard S; Medioni J
    BMC Cancer; 2017 Jan; 17(1):27. PubMed ID: 28061764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus: side effect profile and management of toxicities in breast cancer.
    Paplomata E; Zelnak A; O'Regan R
    Breast Cancer Res Treat; 2013 Aug; 140(3):453-62. PubMed ID: 23907751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
    Kordes S; Klümpen HJ; Weterman MJ; Schellens JH; Richel DJ; Wilmink JW
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1135-41. PubMed ID: 25822310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
    Shameem R; Lacouture M; Wu S
    Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
    Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology.
    Ravaud A; Urva SR; Grosch K; Cheung WK; Anak O; Sellami DB
    Eur J Cancer; 2014 Feb; 50(3):486-95. PubMed ID: 24332451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.